Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator
activity and minimum negative inotropic effects. It is a potent antihypertensive drug when …

Isradipine controlled release (ISR-CR) is a reformulated long-acting dihydropyridine calcium
channel blocker. Its long-term antihypertensive effects and safety were tested in a 52-week …

Isradipine is a dihydropyridine calcium-entry blocker. Previous controlled and blinded trials
have demonstrated the safety and efficacy of isradipine in lowering blood pressure in …

Of the calcium channel blocking drugs, only verapamil is approved in the United States for
treatment of hypertension. Isradipine is a 1, 4-dihydropyridine calcium blocker that may be …

The antihypertensive effect of isradipine compared with placebo was assessed in 28 male
patients (aged 40–64 years) with mild-to-moderate essential hypertension. After withdrawal …

Ambulatory blood pressure monitoring gives a more representative blood pressure profile
than office blood pressure measurements and is free of any placebo effect. It is therefore …

A randomized, double‐blind, placebo controlled study evaluated the effects on 24 h
ambulatory blood pressure (ABP) of isradipine sustained release (I‐SRO) administered …

The efficacy and tolerability of an infusion of isradipine, a calcium antagonist of the
dihydropyridine type, were tested in patients in hypertensive crisis. Ten patients with …

Fifty consecutive black patients with very severe hypertension (sitting diastolic blood
pressure≥ 120 mm Hg and systolic≥ 210 mm Hg by the conventional cuff method) were …

In one study of 10 patients with mild-to-moderate hypertension, equivalent total daily doses
(13±2 mg) of isradipine given twice daily and a modified-release formulation of isradipine …